Growth delay and median survival for all treatments
| Treatment . | Growth delay, d ± SE* . | Median survival, d ± SE . |
|---|---|---|
| NaCl | — | 21 ± 1 |
| rituximab (pooled) | 3 ± 1 | 44 ± 10 |
| 50 kBq/kg 227Th-rituximab | 5 ± 1 | 26 ± 3 |
| 200 kBq/kg 227Th-rituximab† | 17 ± 1 | > 119 |
| 400 kBq/kg 227Th-rituximab† | 15 ± 1 | > 81 |
| 1000 kBq/kg 227Th-rituximab† | 40 ± 7 | 75 ± 11 |
| 200 kBq/kg 227Th-trastuzumab | 0 ± 6 | 15 ± 2 |
| 400 kBq/kg 227Th-trastuzumab | 2 ± 1 | 20 ± 1 |
| 7.5 MBq/kg Zevalin® | 2 ± 2 | 33 ± 4 |
| 15 MBq/kg Zevalin® | 3 ± 1 | 26 ± 1 |
| 30 MBq/kg Zevalin® | 3 ± 1 | 23 ± 3 |
| Treatment . | Growth delay, d ± SE* . | Median survival, d ± SE . |
|---|---|---|
| NaCl | — | 21 ± 1 |
| rituximab (pooled) | 3 ± 1 | 44 ± 10 |
| 50 kBq/kg 227Th-rituximab | 5 ± 1 | 26 ± 3 |
| 200 kBq/kg 227Th-rituximab† | 17 ± 1 | > 119 |
| 400 kBq/kg 227Th-rituximab† | 15 ± 1 | > 81 |
| 1000 kBq/kg 227Th-rituximab† | 40 ± 7 | 75 ± 11 |
| 200 kBq/kg 227Th-trastuzumab | 0 ± 6 | 15 ± 2 |
| 400 kBq/kg 227Th-trastuzumab | 2 ± 1 | 20 ± 1 |
| 7.5 MBq/kg Zevalin® | 2 ± 2 | 33 ± 4 |
| 15 MBq/kg Zevalin® | 3 ± 1 | 26 ± 1 |
| 30 MBq/kg Zevalin® | 3 ± 1 | 23 ± 3 |
— indicates not applicable.
Delay in days to reach a mean tumor size of 1000 mm3 as compared with treatment with NaCl.
Growth delay significantly different from NaCl and rituximab (t test, P < .05) and median survival significantly different from NaCl and rituximab (Mantley-Cox log rank test, P < .001).